We established an innovation incubation platform Fosun Lead in cooperation with Yale professor Xu Tian.
We created a VC fund in cooperation with UC Berkeley and other world-known universities to invest in tech startups, to look for innovation opportunities at the source, and to stockpile projects for R&D and commercialization in Shanghai.
we established a joint venture called Fosun Kite in Shanghai with Kite Pharma, a global leader in the cell immunotherapy, to introduce Yescarta, which is the first U.S. FDA-approved product of Kite, bringing the world’s cutting-edge CAR-T technology for Chinese cancer patients.
We are collaborating with Intuitive Surgical, the global leader in minimally invasive robot-assisted surgeries, to develop and manufacture products for the early diagnosis and treatment of lung cancer.
Fosun Pharma is also directly recruiting the best scientists or incubating talent within its own technical team through an open and win-win mechanism for innovation. For example, Shanghai Henlius, a biological innovation platform of Fosun Pharma, has become the leader of monoclonal antibodies in China today.